Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Shreya Shyam Sundar
Institution:
University at Buffalo, State University of New York
Observed institution:
University at Buffalo, State University of New York
ORCID:
0009-0009-2058-4086
Observed ORCID:
0009-0009-2058-4086
OpenAlex ID:
A5104299066
MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
·
Cancer Research
·
2
Abstract 1324: MECOM a novel player in AR-driven treatment resistant castration-resistant prostate cancer
2025
·
Surendra Gulla
, Tej K. Sharma
, et al.
·
Cancer Research
·
1
Figure S6 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Figure S4 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Table S3 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Table S6 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Data from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Table S2 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Table S5 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Figure S2 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Figure S7 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Figure S3 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Figure S1 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Table S4 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Figure S5 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Table S1 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Abstract 524: An integrative approach to unveiling biomarkers and therapeutic targets identifies novel treatment strategy for advanced prostate cancer
2025
·
Shreya Shyam Sundar
, Ephraim J. Gardner
, et al.
·
Cancer Research
Dynamic changes in proteome activity landscapes in treatment-resistant-prostate cancer
2024
·
Shreya Shyam Sundar
, Surendra Gulla
, et al.
·
Journal of Pharmacology and Experimental Therapeutics
Abstract 1953: Posttranslational modification in glucocorticoid receptor in treatment resistant prostate cancers
2024
·
Surendra Gulla
, Ephraim Gardner
, et al.
·
Cancer Research
Show more works
View as search
Works count:
19
Citation count:
3
H-index:
1
I10-index:
Year
Topic
Type